Literature DB >> 25488905

Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections.

Ila M Saunders1, Amit Lahoti2, Roy F Chemaly3, Cynthia Trevino4, Michael Westmoreland5, Chitra Hosing4.   

Abstract

Cidofovir, a nucleoside analog of deoxycytidine monophosphate, is a water-soluble polar molecule that exhibits antiviral activity against a broad range of DNA viruses. Cidofovir for injection is approved for the treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. The safety and efficacy of topical cidofovir has been described in a limited number of patients. We present two cases of multidrug-resistant herpes simplex virus infections that responded to topical cidofovir therapy yet resulted in irreversible acute kidney injury.
© The Author(s) 2014.

Entities:  

Keywords:  Topical cidofovir; acute kidney injury; herpes simplex virus; immmunocompromised

Mesh:

Substances:

Year:  2014        PMID: 25488905     DOI: 10.1177/1078155214560921

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  2 in total

1.  Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir.

Authors:  Joel B Epstein; Sara Gharapetian; Ali R Rejali; Rachel Zabner; Michael Lill; Dimitrios Tzachanis
Journal:  Support Care Cancer       Date:  2016-05-10       Impact factor: 3.603

2.  Treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir.

Authors:  Christina D Enescu; Sarah Utz Petry; Nathan Nartker; Meena Moossavi
Journal:  JAAD Case Rep       Date:  2021-05-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.